Arora Charan Jeet, Khattak Fakhre Alam, Yousafzai Mohammad Tahir, Ibitoye Bukola Mary, Shumack Stephen
Miranda Medical Centre, Miranda, New South Wales, Australia.
Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Dermatol Ther. 2020 Jul;33(4):e13685. doi: 10.1111/dth.13685. Epub 2020 Jul 14.
Primary studies have presented conflicting results on the efficacy of Janus kinase (JAK) inhibitors in treating atopic dermatitis. Hence, it is important to determine the summary effect of JAK inhibitors in order to guide the clinical application of this potentially beneficial drug. To determine the efficacy of JAK inhibitors in treating atopic dermatitis in all age groups. A systematic review with meta-analyses of randomized controlled trials (RCTs) reporting on the effect of JAK inhibitors on the signs and symptoms of atopic dermatitis were conducted. Six electronic databases, registries, and search engines (PubMed, Cochrane Central Register of Controlled Trials [CENTRAL], Google Scholar, ScienceDirect, Clinical.gov, and WHO ICTRP) were searched from inception to September, 2019. The search terms include "atopic dermatitis," "eczema," and "Janus kinase inhibitor." The search was restricted to humans. A total of 413 studies were identified through the database search and hand-searching. After the selection process, five RCTs were included in this systematic review. A meta-analysis of three studies showed that JAK inhibitors were effective in reducing Eczema Area and Severity Index (P = .0001) and pruritus scores (P = .0001). JAK inhibitors appear to be effective in treating atopic dermatitis. Future studies should aim to evaluate its cost-effectiveness and availability to patients especially in developing countries.
关于Janus激酶（JAK）抑制剂治疗特应性皮炎的疗效，初步研究给出了相互矛盾的结果。因此，确定JAK抑制剂的总体疗效对于指导这种可能有益的药物的临床应用很重要。为了确定JAK抑制剂在所有年龄组中治疗特应性皮炎的疗效。我们对报告JAK抑制剂对特应性皮炎体征和症状影响的随机对照试验（RCT）进行了系统评价和荟萃分析。从开始到2019年9月，检索了六个电子数据库、注册库和搜索引擎（PubMed、Cochrane对照试验中央注册库[CENTRAL]、谷歌学术、ScienceDirect、Clinical.gov和世界卫生组织国际临床试验注册平台[WHO ICTRP]）。检索词包括“特应性皮炎”、“湿疹”和“Janus激酶抑制剂”。检索仅限于人类。通过数据库检索和手工检索共识别出413项研究。经过筛选过程，五项RCT被纳入本系统评价。三项研究的荟萃分析表明，JAK抑制剂在降低湿疹面积和严重程度指数（P = .0001）和瘙痒评分（P = .0001）方面有效。JAK抑制剂似乎对治疗特应性皮炎有效。未来的研究应旨在评估其成本效益以及患者尤其是发展中国家患者的可及性。
